MDxHealth CEO receives 942,200 option awards

MDxHealth SA Chief Executive Officer Michael McGarrity received two share option awards as equity compensation.

Rhea-AI Filing Summary

MDxHealth SA Chief Executive Officer Michael McGarrity received two share option awards as equity compensation. He was granted 612,400 options and 329,800 options, each exercisable for ordinary shares at an exercise price of $0.76 per share and expiring on May 28, 2036. One grant vests based on Company performance criteria evaluated by the Board at the end of specified performance periods, while the other vests in three equal annual installments on the first three anniversaries of the grant date. These are grants/awards rather than open‑market purchases or sales, and no dispositions were reported in this filing.

Insider Trade Summary

Grant/Award: 942,200 shares

Grant/Award 2 txns

Insider McGarrity Michael

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option	329,800	$0.00	$0.00
Grant/Award	Share Option	612,400	$0.00	$0.00

Holdings After Transaction: Share Option — 942,200 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
2. F2. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

Key Figures

Performance-based options granted: 612,400 options at $0.76/share Time-based options granted: 329,800 options at $0.76/share Total options reported after grants: 612,400 options (first grant), 329,800 options (second grant) +2 more

5 metrics

Performance-based options granted 612,400 options at $0.76/share Grant to CEO on June 1, 2026; vests on performance criteria

Time-based options granted 329,800 options at $0.76/share Grant to CEO on June 1, 2026; vests over three years

Total options reported after grants 612,400 options (first grant), 329,800 options (second grant) Holdings following each respective grant

Option exercise price $0.76 per share Exercise price for both MDxHealth CEO option grants

Option expiration date May 28, 2036 Expiration for both share option awards

Key Terms

Share Option, ordinary shares, performance criteria, three equal installments, +1 more

5 terms

Share Option financial

"security_title: "Share Option" for both derivative transactions"

ordinary shares financial

"Represents options to purchase ordinary shares at a price per share of $0.76"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

performance criteria financial

"options vest upon the achievement of certain Company performance criteria evaluated by the Board"

three equal installments financial

"options vest in three equal installments on each of the first three anniversaries"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MDXH CEO Michael McGarrity report on this Form 4?

Michael McGarrity reported receiving two share option awards, not buying or selling stock in the market. The grants provide rights to acquire MDxHealth ordinary shares in the future, subject to vesting conditions and an exercise price of $0.76 per share.

How many share options did MDXH grant to CEO Michael McGarrity?

He was granted 612,400 share options in one award and 329,800 share options in a second award. In total, the Form 4 shows 942,200 options, each relating to MDxHealth ordinary shares, subject to separate vesting schedules and conditions described in the footnotes.

What is the exercise price and expiration date of Michael McGarrity’s MDXH options?

Both option grants have an exercise price of $0.76 per ordinary share and share the same expiration date of May 28, 2036. This means McGarrity may choose to exercise vested options at that price any time before the expiration date.

How do the MDXH option grants to Michael McGarrity vest?

One option grant vests upon achievement of specified Company performance criteria, evaluated by the Board after relevant performance periods. The second grant vests in three equal installments on each of the first three anniversaries of the grant date, creating a time-based vesting schedule.

Did Michael McGarrity buy or sell MDXH shares in this Form 4 filing?

The filing reports only grant or award acquisitions of share options, not open-market purchases or sales of MDxHealth shares. There are no selling transactions or tax-withholding dispositions disclosed, indicating this Form 4 reflects compensation-related awards rather than trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGarrity Michael

(Last) (First) (Middle)

CAP BUSINESS CENTER

ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)

HERSTAL BELGIUM 4040

(City) (State) (Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$0.76	06/01/2026		A		329,800		(1)	05/28/2036	Ordinary Shares	329,800	$0	329,800	D
Share Option	$0.76	06/01/2026		A		612,400		(2)	05/28/2036	Ordinary Shares	612,400	$0	612,400	D

Explanation of Responses:

1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

2. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

	/s/ Mark Busch, as attorney-in-fact for Michael McGarrity	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)